Cargando…

Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines

BACKGROUND: Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy-Martin, Matthew, Slaap, Bernhard, Herdman, Michael, van Reenen, Mandy, Kennedy-Martin, Tessa, Greiner, Wolfgang, Busschbach, Jan, Boye, Kristina S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561556/ https://www.ncbi.nlm.nih.gov/pubmed/32514643 http://dx.doi.org/10.1007/s10198-020-01195-8

Ejemplares similares

EQ-5D: a plea for accurate nomenclature
por: Brooks, Richard, et al.
Publicado: (2020)

Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
por: Sims, Tracy J, et al.
Publicado: (2022)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments
por: Kwon, Joseph, et al.
Publicado: (2023)

The Utility of a Rapid Review Evaluation Process to a National HTA Agency
por: Varley, Áine, et al.
Publicado: (2021)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

A New Approach to Assessing Children’s Interpretation of Severity Qualifiers in a Multi-Attribute Utility Instrument–The EQ-5D-Y-5L: Development and Testing
por: Derrett, Sarah, et al.
Publicado: (2021)

Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and ‘micro-utility’ effects
por: Richardson, Jeff, et al.
Publicado: (2015)

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2017)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review
por: Kennedy-Martin, Tessa, et al.
Publicado: (2017)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
por: Xie, Feng, et al.
Publicado: (2015)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Validity and Reliability of the Assessment of Quality of Life (AQoL)-8D Multi-Attribute Utility Instrument
por: Richardson, Jeff, et al.
Publicado: (2013)

Development of a multiplicative, multi-attribute utility function and eight single-attribute utility functions for the Health Utilities Index Mark 3 in Japan
por: Noto, Shinichi, et al.
Publicado: (2020)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

From recommendation to action: psychosocial factors influencing physician intention to use Health Technology Assessment (HTA) recommendations
por: Gagnon, Marie-Pierre, et al.
Publicado: (2006)

Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review
por: Boye, Kristina S, et al.
Publicado: (2022)

Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2018)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

Psychometric Performance of Generic Childhood Multi-Attribute Utility Instruments in Preterm and Low Birthweight Populations: A Systematic Review
por: Kwon, Joseph, et al.
Publicado: (2023)

Time to publication for NIHR HTA programme-funded studies
por: Chinnery, Fay, et al.
Publicado: (2013)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

CONSORT: missing missing data guidelines, the effects on HTA monograph reporting
por: Sylvestre, Yvonne
Publicado: (2011)

Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
por: Yuba, Tania Yuka, et al.
Publicado: (2018)

What are the characteristics of an application (or team) which are associated with success or failure of an application to the NIHR HTA programme for research funding?
por: Turner, Sheila, et al.
Publicado: (2011)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_der7gjdp5671i6gkvk68ku5j59